Change in Preferred Drug List Status for the Smoking Cessation Drug Class Effective May 16, 2023
HHSC is aware of a drug shortage for the brand name Chantix in the Smoking Cessation drug class due to a manufacturing delay of this product by Pfizer. We received reports of a shortage from managed care organizations (MCOs), and verified it with the manufacturer.
In response to the preferred brand name Chantix shortage, HHSC removed the non-preferred status from the generic product, varenicline, on the preferred drug list (PDL). The preferred status of the brand name Chantix products (NDC 00069-0468-56, 00069-0471-03, 00069-0469-56) will not change to allow for any existing stock available to be utilized. HHSC removed the non-preferred status for the following generic drugs, effective May 16, 2023, and HHSC will reflect these changes in the daily formulary file for MCOs.
|Generic Drug Name
|Varenicline 0.5 mg tablet
|Varenicline 1 mg tablet
|Varenicline starting month box
These changes will allow providers to prescribe the generic varenicline without requiring a PDL prior authorization and continue accessing necessary medication for clients.